Longus
Tak różowo jednak z CLA nie jest – oto trochę więcej opisów badań - generalnie wszystkie potwierdzają skuteczność cla, jednak mnie trochę przeraziły te powiększone wątroby i nerki u badanych myszek, świnek i chomików, no i ta oporność na insulinę u zdrowych ludzi...bo diabetykom akurat cla pomaga...
Insulin resistance - Proponents of CLA often quote studies in which it improves insulin sensitivity in rat models of diabetes [1-2, 4]. Additionally, CLA favorably alters metabolic parameters in humans with type II diabetes [2]. Unfortunately the opposite effect is seen in nondiabetic individuals. Induction of insulin resistance, or markers thereof, has been noted in pigs, mice, hamsters, and rats fed CLA despite fat loss [1-2, 4]. Even in a study in pigs in which there were no changes in body composition, fasting insulin rose by 37% [4]. Additionally, 3.4 g daily of t10,c12 CLA for 12 weeks increased insulin resistance (by 19%) and C-reactive protein (a marker of inflammation and predictor of cardiovascular risk) in obese men [1, 13]. This effect may be related with increased levels of TNF-alpha [4]. It can be concluded that although CLA is beneficial to those with diabetes, it may increase insulin resistance in normoglycemic individuals.
Other effects - There are a variety of other effects of CLA. On the positive side, CLA reduces bone inflammation [14] and has a positive role in bone formation in rats [2]. CLA also appears to improve immune response in healthy men [15] and protects against end-stage symptoms of lupus erythematosis, although it accelerates the onset of this condition [2]. Multiple studies have found CLA to increase markers of lipid peroxidation and oxidative stress in both healthy and obese humans, an effect which is not reduced by vitamin E [1-2, 16-17]. Additionally, CLA causes liver steatosis (fat accumulation) in mice and chicken and liver and kidney enlargement in hamsters despite a decrease in body weight, and this effect has been attributed to the t10,c12 isomer [1-2, 18].
I jeszcze wyniki duńskich badań z 2003 roku, potwierdzające niestety zagrożenie przerostu wątroby ze strony izomeru trans-10, cis 12:
Efficacy and safety of dietary supplements containing CLA for the treatment of obesity: evidence from animal and human studies.
Larsen TM, Toubro S, Astrup A.
Department of Human Nutrition, Center for Advanced Food Studies, The Royal Veterinary and Agricultural University, DK-1958 Frederiksberg C, Denmark.
Dietary supplements containing conjugated linoleic acid (CLA) are widely promoted as weight loss agents available over the counter and via the Internet. In this review, we evaluate the efficacy and safety of CLA supplementation based on peer-reviewed published results from randomized, placebo-controlled, human intervention trials lasting more than 4 weeks. We also review findings from experimental studies in animals and studies performed in vitro. CLA appears to produce loss of fat mass and increase of lean tissue mass in rodents, but the results from 13 randomized, controlled, short-term (<6 months) trials in humans find little evidence to support that CLA reduces body weight or promotes repartitioning of body fat and fat-free mass in man. However, there is increasing evidence from mice and human studies that the CLA isomer trans-10, cis-12 may produce liver hypertrophy and insulin resistance via a redistribution of fat deposition that resembles lipodystrophy. CLA also decreases the fat content of both human and bovine milk. In conclusion, although CLA appears to attenuate increases in body weight and body fat in several animal models, CLA isomers sold as dietary supplements are not effective as weight loss agents in humans and may actually have adverse effects on human health.
PMID: 12923219 [PubMed - in process]
Pozdrowienia
Longus
Insulin resistance - Proponents of CLA often quote studies in which it improves insulin sensitivity in rat models of diabetes [1-2, 4]. Additionally, CLA favorably alters metabolic parameters in humans with type II diabetes [2]. Unfortunately the opposite effect is seen in nondiabetic individuals. Induction of insulin resistance, or markers thereof, has been noted in pigs, mice, hamsters, and rats fed CLA despite fat loss [1-2, 4]. Even in a study in pigs in which there were no changes in body composition, fasting insulin rose by 37% [4]. Additionally, 3.4 g daily of t10,c12 CLA for 12 weeks increased insulin resistance (by 19%) and C-reactive protein (a marker of inflammation and predictor of cardiovascular risk) in obese men [1, 13]. This effect may be related with increased levels of TNF-alpha [4]. It can be concluded that although CLA is beneficial to those with diabetes, it may increase insulin resistance in normoglycemic individuals.
Other effects - There are a variety of other effects of CLA. On the positive side, CLA reduces bone inflammation [14] and has a positive role in bone formation in rats [2]. CLA also appears to improve immune response in healthy men [15] and protects against end-stage symptoms of lupus erythematosis, although it accelerates the onset of this condition [2]. Multiple studies have found CLA to increase markers of lipid peroxidation and oxidative stress in both healthy and obese humans, an effect which is not reduced by vitamin E [1-2, 16-17]. Additionally, CLA causes liver steatosis (fat accumulation) in mice and chicken and liver and kidney enlargement in hamsters despite a decrease in body weight, and this effect has been attributed to the t10,c12 isomer [1-2, 18].
I jeszcze wyniki duńskich badań z 2003 roku, potwierdzające niestety zagrożenie przerostu wątroby ze strony izomeru trans-10, cis 12:
Efficacy and safety of dietary supplements containing CLA for the treatment of obesity: evidence from animal and human studies.
Larsen TM, Toubro S, Astrup A.
Department of Human Nutrition, Center for Advanced Food Studies, The Royal Veterinary and Agricultural University, DK-1958 Frederiksberg C, Denmark.
Dietary supplements containing conjugated linoleic acid (CLA) are widely promoted as weight loss agents available over the counter and via the Internet. In this review, we evaluate the efficacy and safety of CLA supplementation based on peer-reviewed published results from randomized, placebo-controlled, human intervention trials lasting more than 4 weeks. We also review findings from experimental studies in animals and studies performed in vitro. CLA appears to produce loss of fat mass and increase of lean tissue mass in rodents, but the results from 13 randomized, controlled, short-term (<6 months) trials in humans find little evidence to support that CLA reduces body weight or promotes repartitioning of body fat and fat-free mass in man. However, there is increasing evidence from mice and human studies that the CLA isomer trans-10, cis-12 may produce liver hypertrophy and insulin resistance via a redistribution of fat deposition that resembles lipodystrophy. CLA also decreases the fat content of both human and bovine milk. In conclusion, although CLA appears to attenuate increases in body weight and body fat in several animal models, CLA isomers sold as dietary supplements are not effective as weight loss agents in humans and may actually have adverse effects on human health.
PMID: 12923219 [PubMed - in process]
Pozdrowienia
Longus
Pozdrowienia
LONGUS
ambroziak
kanarek
Czarnuchok
misOO
widocznie jeszcze nie jest to ustalone...przeciez oni to sprzedaja czlowieku to czemu by mieli specjalnie ukrywac cene ? w koncu chca zarobic...skoro produktu jeszcze nie ma na rynku to i ceny nie ma...
FaT-JoE
